Co-administration of antihypertensive drug therapy and hormonal replacement therapy (HRT) is frequent in postmenopausal women but it is not known whether HRT interacts with concomitant antihypertensive therapy. The present study was designed to investigate efficacy and safety of the ACE inhibitor moexipril in comparison to placebo in hypertensive, postmenopausal women on HRT.
Introduction
One very important question facing postmenopausal women today is whether or not to take hormone replacement therapy (HRT). Its benefits include reduced risk of cardiovascular disease and osteoporosis as well as control of postmenopausal symptoms. [1] [2] [3] [4] Otherwise, risk of endometrial cancer is greatly increased with unopposed oestrogen treatment, and breast cancer is increased with both forms of HRT (oestrogen alone or oestrogen plus progestin). 5, 6 The risk/benefit ratio of HRT has yet to be assessed in prospective trials.
Despite the benefits of HRT in relieving menopausal symptoms, there continues to be anxiety about its use in women who also have hypertension. Although there is overwhelming evidence that HRT reduces the incidence, many physicians assume that Correspondence: Professor Michael Stimpel, MD, Schwarz Pharma Deutschland GmbH, Alfred-Nobel-Straβe 10, 40789 Monheim, Germany Received 8 October 1998; revised 31 December 1998; accepted 8 February 1999 and diastolic BP from baseline than placebo (−12.2/ −9.9 mm Hg vs −1.6/−4.3 mm Hg, P Ͻ 0.001). Metabolic parameters were not affected by treatment with moexipril: mean levels of triglycerides, total cholesterol, HDL, LDL, total cholesterol/HDL ratio and glucose remained unchanged throughout the study. Fibrinogen, an independent cardiovascular risk factor, increased after placebo (+35.0 mg/dl) and decreased after treatment with moexipril (−33.6 mg/dl), the difference, however, was not statistically significant. Moexipril was well-tolerated by postmenopausal women using HRT. The most frequent adverse events included headache (21.3%), cough (12.8%) and rhinitis (10.6%) and there were no significant differences in the number and severity of adverse events between the moexipril and placebo groups.
This study indicates that moexipril is effective and well tolerated in the treatment of hypertensive, postmenopausal women and can safely be co-administered to HRT.
it may cause hypertension, perhaps under the mistaken impression that HRT has the same side effects as the first generation of steroid contraceptives. A number of newer case-control and prospective studies have demonstrated that HRT does not exacerbate hypertension in postmenopausal women and that cardiovascular mortality of postmenopausal women on HRT decreases by approximately one-half. [7] [8] [9] Unfortunately up to now very little is known about the interaction of HRT and antihypertensive drug treatment. Therefore the present placebo-controlled study was designed to answer the question whether the new angiotensin-converting enzyme (ACE) inhibitor, moexipril, can effectively and safely be co-administered to HRT in the antihypertensive drug treatment of postmenopausal women. The compatibility of both drug therapies was studied with respect to blood pressure (BP), metabolic parameters and special clotting factors.
Patients and methods

Patients
This randomised, double-blind, parallel, placebocontrolled study was conducted at 12 centres in the United States. The study population consisted of postmenopausal women with mild to moderate hypertension (sitting diastolic BP between 95 and 114 mm Hg) who were treated with HRT. The majority of patients received oestrogen therapy alone (54/95) or a combination of oestrogen and progestin (33/95), as prescribed by their physician.
Patients had to be free of secondary hypertension or any significant cardiovascular, haematologic, endocrinologic, hepatic or renal disease. Patients were also excluded for alcohol or drug abuse, concomitant medication that influenced BP, any abnormalities that may interfere with absorption or contraindication to treatment with any of the study drugs.
Study design
Before entering the study, all patients signed a written informed consent form, approved by the review boards of the participating institutions. At this point, all previous antihypertensive medications, when applicable, were discontinued in a 1 week wash-out period with the use of appropriate tapering procedures. This was followed by a 4 week single-blind placebo period. At the conclusion of the placebo period, 95 patients with a sitting diastolic BP between 95 to 114 mm Hg were randomised to receive moexipril 15 mg or placebo. The patients were followed-up in the clinic at weekly intervals during the wash-out and placebo period and every 2 or 4 weeks during the 12 week double-blind treatment phase. Initial and final visit evaluations included a medical history, physical examination with a fundoscopy, laboratory evaluations and a 12 lead ECG. Blood pressure and heart rate were measured at each of the seven visits. The study drugsmoexipril or matching placebo-were taken once daily, approximately at the same time of the day, compliance was assessed by pill counting. HRT was continued unchanged throughout the study.
Blood pressure measurement
Blood pressure measurement was conducted in accordance with the American Society of Hypertension recommendations with a standard mercury sphygmomanometer. Triplicate BP measurements were taken in the sitting position after 5 min of rest. The recorded BP was an average of these three readings. Standing BP was determined immediately following standing up from the sitting position and repeated 2 min later while still remaining upright. Phase I and V of the Korotkoff sounds were used as the determinants of systolic and diastolic BP, respectively. Pulse was also recorded once in the sitting and once in the standing position. Blood pressure and heart rate were assessed for all visits at similar times of day, preferably in the morning 24 ± 2 h after the prior days dose. Efforts were made to ensure the consistency of the environment.
Laboratory measurements
Twelve hour fasting blood specimens and a urinalysis were obtained at the start of the placebo period, at baseline and at week 4 and 12 of the double-blind treatment period. Specimens were taken for measurement of triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, total cholesterol/HDL ratio and fasting serum glucose. Blood samples also were evaluated for special coagulation studies, eg, plasminogen activator inhibitor-1 (PAI-1), lipoprotein (a), antithrombin III, protein C, protein S and fibrinogen.
Adverse experiences
Adverse experiences as well as pre-vs post-treatment results of physical examination, ECG and laboratory tests (biochemistry, haematology, urinalysis and special clotting factors) were included in the safety evaluation. Adverse events were assessed at each visit and graded by the investigator as 'serious' or 'non-serious', and 'mild', 'moderate' or 'severe' and the relationship to the study medication was characterised as 'none', 'likely', 'possible', 'probable' or 'highly probable'.
Statistical methods
Continuous variables were summarised with descriptive statistics (eg, number, mean, median, standard deviation, minimum and maximum). Treatment comparisons were inferentially analysed using a two-way analysis of variance model (ANOVA) with fixed effects for site, treatment, and treatment per site interaction. Changes in sitting systolic and diastolic BP and heart rate were analysed by analysis of covariance (ANCOVA) with factors for site, treatment, and treatment per site interaction, using the baseline measure as a covariate. Response rates were analysed by using the Cochran-MantelHaenszel Test for general association. The primary analyses as well as the assessment of the adverse events were performed on an intent-to-treat basis. Comparison between treatment groups for each category of adverse events was performed using the Fisher's Exact Test. All tests were two-sided and Pvalues Ͻ0.05 were considered significant.
Results
Baseline demographics
Of 129 postmenopausal women initially screened for study entry, 95 met the entry criteria and were randomised to treatment with moexipril 15 mg (47 patients) or placebo (48 patients). Seventy-eight (78) patients completed the 12 week double-blind period; 12 patients from the placebo group and five patients from the moexipril group discontinued the study. Table 1 displays baseline demographics and vital signs of the randomised patients. The distribution of race and age was similar in the two assigned treatment groups. Patients ranged in age from 35 to 74 years and the majority were white (72% and 73% in the moexipril and the placebo group, respectively) and of medium frame size. 
Efficacy
Mean baseline systolic and diastolic BPs were 154.6/99.5 mm Hg for the moexipril group and 158.5/100.1 mm Hg for the placebo group. After 12 weeks of treatment, moexipril reduced both the diastolic BP (−9.9 mm Hg vs −4.3 mm Hg, P Ͻ 0.001) and the systolic BP (−12.2 mm Hg vs −1.6 mm Hg, P Ͻ 0.001) to a statistically significantly greater extent than did placebo (Figure 1 ). Changes in systolic and diastolic BP in the standing and 2-min standing positions were similar to those seen in the sitting position. Also the response rates for moexipril and placebo differed significantly. Response rates are classified as excellent if the patient has a sitting diastolic BP Ͻ90 mm Hg and as good if the sitting diastolic BP is у90 mm Hg but a BP reduction of у10 mm Hg is achieved. Fifty-one percent (51%) of the patients treated with 15 mg moexipril had an excellent response to treatment and good response was seen in 2%. The respective values were 25% and 11% in the placebo group. Table 2 displays the laboratory data for the treatment groups. Moexipril in general did not affect metabolic parameters. Mean levels of triglycerides, total cholesterol, HDL, LDL, total cholesterol/HDL ratio and glucose remained relatively unchanged throughout the study. Moexipril treated patients showed a moderate decrease in mean levels of fibrinogen compared to patients receiving placebo (−33.6 mg/dl vs +35.0 mg/dl) ( Table 3) ; the difference however was not statistically significant. No significant changes in plasminogen activator inhibitor (PAI), lipoprotein (a), antithrombin III, protein C or protein S were observed in either treatment group. ECHO and physical examination results indicated no significant changes from baseline for either group, nor significant differences between both groups at either baseline or week 12.
Safety
Moexipril was well tolerated by postmenopausal women using HRT. Adverse event rates for moexipril and placebo were in general similar. The overall percentages of patients who had one or more laboratory adverse events during the double-blind period were 19.1% for moexipril and 16.7% for placebo. For clinical adverse events the overall percentages were 70.2% for moexipril and 58.3% for placebo. The most frequent adverse events included headache (21.3%), cough (12.8%) and rhinitis (10.6%) for moexipril and headache (27.1%) and pharyngitis (8.3%) for placebo. There were no significant differences in the number or severity of adverse events between the moexipril and placebo groups, except for increased cough (12.8% of moexipril patients vs no placebo patients).
Discussion
After losing the protective effect of oestrogens, postmenopausal women are at an increased risk of developing cardiovascular diseases, osteoporosis and metabolic disturbances such as dyslipidaemia. [10] [11] [12] Long-term administration of HRT may reduce the risk of developing these conditions via favourable effects on bone metabolism and cardiovascular risk factors (ie, raising HDL, lowering of LDL, total cholesterol, fibrinogen and PAI-1, 1, [13] [14] [15] [16] ). Additionally, HRT relieves postmenopausal symptoms such as vaginal dryness, loss of libido, hot flushes and depression. [1] [2] [3] [4] Although results from some studies in women on opposed or unopposed postmenopausal oestrogen therapy also showed a slight beneficial effect of HRT on high BP, 17 most studies indicate that HRT has little effect on BP in either normotensive or hypertensive subjects. 1, 9 Therefore for postmenopausal women suffering from hypertension, concomitant long-term treatment with HRT and antihypertensive drugs may be required. Up to now no data exists about the effects of co-administrated HRT and antihypertensive drug treatment. Therefore the current study concentrated on the effect of the new ACE inhibitor moexipril vs placebo on BP, cardiovascular risk factors and the safety profile in women co-treated with HRT. An ACE inhibitor was chosen for investigation as ACE inhibitors seem to be preferred drugs in postmenopausal women as they are effective, well-tolerated and free of metabolic adverse events.
Patients receiving moexipril for the 12-week study period had statistically significant and clinically relevant mean decreases from baseline in systolic and diastolic BP (−12.2/−9.9 mm Hg). These reductions were comparable to those reported previously for the same dose of moexipril [18] [19] [20] and were statistically significantly greater than for placebo (−1.6/−4.3 mm Hg; P Ͻ 0.001). Compared to placebo, greater numbers of moexipril patients (51% vs 25%) had a response rate categorised as excellent. These results are similar to those obtained with moexipril in placebo controlled studies in other patient populations 18, 21, 22 and thereby indicate moexipril as effective in reducing BP in postmenopausal women who concomitantly receive HRT. The effects of HRT per se on BP were not assessed in the study, as HRT regimens were held constant throughout all of the experimental period.
Previous studies have demonstrated slightly favourable metabolic effects of HRT on HDL, LDL and fibrinogen levels when studied in postmenopausal women over different periods of time up to 1 year. [1] [2] [3] [4] This short-term study, however, failed to show any significant positive effect on lipid and glucose metabolism in its placebo-treated patients as all patients were stable on their individual HRT treatment prior to start of study. Moreover, the current study showed that addition of moexipril did not affect any metabolic parameter. ACE inhibitors like moexipril in general are not associated with any metabolic abnormalities [22] [23] [24] and this study proved that this is also true in combination with HRT. Mean levels of triglycerides, total cholesterol, HDL, LDL, total cholesterol/HDL ratio and glucose remained relatively unchanged throughout the study which indicates that with regard to cardiovascular risk factors both drugs can safely be co-administered.
After menopause the haemostatic balance shifts towards a latent hypercoagulable state and especially fibrinogen and PAI-1, a primary inhibitor of fibrinolysis, appear to rise. Both clotting factors are positively linked to the risk of coronary heart disease. 25, 26 Postmenopausal women receiving HRT showed to have more favourable plasma levels of the haemostatic factors PAI-1 and fibrinogen than did those not receiving therapy. 16, 27, 28 Thus, the putative beneficial effect of HRT on the risk of coronary heart disease may be partly mediated through the proven changes in clotting factors and the fibrinolytic system. Changes in special coagulation parameters evaluated in this study did not reveal any statistical significance neither in patients treated concomitantly with moexipril nor in patients receiving placebo and no significant difference was observed in the between-treatment evaluations. Nevertheless, mean fibrinogen levels seen in the moexipril treated patients were moderately decreased compared to patients receiving HRT only (−33.6 mg/dl vs +35.0 mg/dl). The difference was not statistically significant. As the plasma fibrinogen level is associated with both the severity and the extent of coronary, cerebral and peripheral atherosclerosis, 4, 26, 29 these results may indicate that co-administration of moexipril and HRT is of possible protective effect regarding that. Fibrinogen levels, however, are positively correlated with age, smoking behaviour, diabetes, hypertension, obesity and hypercholesterolaemia whereas alcohol intake and oestrogen replacement therapy are associated with lower fibrinogen concentrations. [30] [31] [32] Therefore, further evaluations are necessary to ensure that this interesting finding is of real clinical relevance. Nevertheless, the fact that other investigators also showed a favourable effect of ACE inhibitors on fibrinogen levels 33 seems to be encouraging. Overall, moexipril was well tolerated among postmenopausal women using HRT, the adverse event rate was similar to previous moexipril studies [18] [19] [20] [21] [22] and no new safety risks were identified during the course of this study. Especially, no effect of moexipril on the typical postmenopausal symptoms could be observed. The percentage of clinical adverse events, however, was slightly higher in the moexipril than in the placebo group (70% vs 58%). The difference may be due in part to the incidence of cough in moexipril-treated patients. Increased cough was the only adverse event for which any significant difference was demonstrated between the groups (12.8% of moexipril patients vs no placebo patients). Cough is a well documented side effect of ACE inhibitors and an expected adverse event for moexipril in the whole population. [34] [35] [36] [37] Although the ability is limited to extrapolate the findings to other HRT groups than those examined, this study indicates that moexipril is effective and well-tolerated in the treatment of hypertensive, postmenopausal women and can safely be co-administered to individuals taking HRT. Nevertheless, the interaction of ACE inhibition and HRT during longterm administration in postmenopausal women remains an outstanding topic which requires further research.
